TJ Cradick
Chief Scientific Officer Gene Editing Frontiers
Dr. TJ Cradick is a recognized leader in gene editing with more than two decades of driving innovations in engineering nucleases, gene editing assays and gene therapy technology development. He played pivotal roles in advancing Zinc Finger Nucleases, TALENs, and CRISPR/Cas systems at Sangamo BioSciences, Georgia Tech, and CRISPR Therapeutics.
Notably, his work at CRISPR Therapeutics was instrumental in the initiation and development of Casgevy, the first approved CRISPR therapy. Dr. Cradick continues to shape the field, having served as CSO at Excision BioTherapeutics (first in vivo, multiplex editing), CTO at HuidaGene Therapeutics (novel DNA and RNA editors), and as the principal consultant with Gene Editing Frontiers, LLC.
Seminars
- Learning from both setbacks and successes to accelerate the field as one
- Exploring real-world examples of programs that pivoted and re-engaged with regulators
- Sharing lessons learned from teams that had to change endpoints and still move forward
